Claims for Patent: 6,333,333

Summary for Patent: 6,333,333

Title:	Methods for treating proliferative diseases
Abstract:	Methods are provided for treating proliferative diseases, especially cancers, comprising administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an antineoplastic agent and/or radiation therapy.
Inventor(s):	Bishop; Walter R. (Pompton Plains, NJ), Catino; Joseph J. (Guilford, CT), Doll; Ronald J. (Maplewood, NJ), Ganguly; Ashit (Upper Montclair, NJ), Girijavallabhan; Viyyoor M. (Parsippany, NJ), Kirschimeier; Paul (Basking Ridge, NJ), Liu; Ming (Fanwood, NJ), Nielsen; Loretta L. (Millington, NJ), Cutler; David L. (Morristown, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	09/503,513
Patent Claims:	1. A method of treating a proliferative disease in a patient in need of such treatment, said treatment comprising administering, concurrently or sequentially, an effective amount of (1) a FPT inhibitor and (2) an antineoplastic agent and/or radiation therapy; wherein the FPT inhibitor comprises a compound having the formula (I) or (III): ##STR220## where, X.sub.1, X.sub.2 and X.sub.3, independently of one another, are each a hydrogen, chlorine or bromine atom; the dotted line between Z and the 7-membered carbocyclic ring represents a single or double bond; Z is a nitrogen atom or a CH radical when the bond between Z and the 7-membered carbocyclic ring is a single bond; Z is a C radical when the bond between Z and the 7-membered carbocyclic ring is a double bond; Y.sub.1 = ##STR221## where R.sub.1 is a hydrogen atom or a lower alkyl, --CONH.sub.2 or --COR.sub.2 group, where R.sub.2 is a lower alkyl group, or Y.sub.1 = ##STR222## or one of its isomers in the 1, 2 or 3 position; R.sub.6 is a --NR.sub.7 (CH.sub.2).sub.n --R.sub.4 group, where n is 2 or 3; R.sub.4 is a ##STR223## group attached at the 1, 2, 4 or 5 position, where R.sub.5 is a hydrogen atom or a lower alkyl group; and R.sub.7 is a hydrogen atom or an alkyl group substituted with a phenyl group, or R.sub.6 is ##STR224## where R.sub.4 is defined the same as above; and Y.sub.2 is a X.sub.6 -cycloalkyl group, where X.sub.6 is a CH.sub.2, O or NH group; with the proviso that the FPT inhibitor is not the following compound: ##STR225## 2. The method of claim 1 wherein the FPT inhibitor is a compound having the formula (I): ##STR226## where, X.sub.1, X.sub.2, X.sub.3, Z, Y.sub.1 and the dotted line are defined the same as above. 3. The method of claim 50 wherein the FPT inhibitor is a compound having the formula (III): ##STR227## where, X.sub.1, X.sub.2, X.sub.3, Y.sub.2 and R.sub.6 are defined the same as above. 4. The method of claim 1 wherein said FPT inhibitor, and said antineoplastic agent and/or radiation are administered concurrently. 5. The method of claim 1 wherein said FPT inhibitor, and said antineoplastic agent and/or radiation are administered simultaneously. 6. The method of claim 1 wherein said FPT inhibitor, and said antineoplastic agent and/or radiation are administered sequentially. 7. The method of claim 1 wherein said antineoplastic agent and/or radiation therapy is administered first. 8. The method of claim 1 wherein said FPT inhibitor is administered first. 9. The method of claim 1 wherein said proliferative disease is: lung cancer, pancreatic cancer, colon cancer, myeloid leukemia, melanoma, thyroid follicular cancer, bladder carcinoma, glioma, myelodysplastic syndrome, breast cancer or prostate cancer. 10. The method of claim 1 wherein said antineoplastic agent is selected from: Uracil mustard, Chlormethine, Cyclophosphamide, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Temozol-omide, Methotrexate, 5-Fluorouracil, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Gemcitabine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Paclitaxel, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Interferons, Etoposide, Teniposide 17-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Tamoxifen, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, Goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine. 11. The method of claim 1 wherein said antineoplastic agent is 5-Fluorouracil. 12. The method of claim 1 wherein said antineoplastic agent is temozolomide. 13. The method of claim 1 wherein said radiation is .gamma.-radiation. 14. A method of treating a proliferative disease in a patient in need of such treatment, said treatment comprising administering, concurrently or sequentially, an effective amount of (1) a FPT inhibitor and (2) gemcitabine; wherein the FPT inhibitor is a compound having the formula (I) or (III): ##STR228## where, X.sub.1, X.sub.2 and X.sub.3, independently of one another, are each a hydrogen, chlorine or bromine atom; the dotted line between Z and the 7-membered carbocyclic ring represents a single or double bond; Z is a nitrogen atom or a CH radical when the bond between Z and the 7-membered carbocyclic ring is a single bond; Z is a C radical when the bond between Z and the 7-membered carbocyclic ring is a double bond; Y.sub.1 = ##STR229## where R.sub.1 is a hydrogen atom or a lower alky, --CONH.sub.2 or --COR.sub.2 group, where R.sub.2 is a lower alkyl group, or Y.sub.1 = ##STR230## or one of its isomers in the 1, 2 or 3 position; R.sub.6 is a --NR.sub.7 (CH.sub.2).sub.n --R.sub.4 group, where n is 2 or 3; R.sub.4 is a ##STR231## group attached at the 1, 2, 4 or 5 position, where R.sub.5 is a hydrogen atom or a lower alkyl group; and R.sub.7 is a hydrogen atom or an alkyl group substituted with a phenyl group, or R.sub.6 is ##STR232## where R.sub.4 is defined the same as above; and Y.sub.2 is a X.sub.6 -cycloalkyl group, where X.sub.6 is a CH.sub.2, O or NH group; with the proviso that the FPT inhibitor is not the following compound: ##STR233## 15. The method of claim 14 wherein the proliferative disease is an epithelial cancer. 16. The method of claim 14 wherein the proliferative disease is: prostate cancer, lung cancer, or pancreatic cancer. 17. The method of claim 14 wherein the proliferative disease is pancreatic cancer. 18. The method of claim 1, wherein the antineoplastic agent is a microtubule affecting agent. 19. The method of claim 18 wherein the microtubule affecting agent is paclitaxel or a paclitaxel derivative. 20. The method of claim 18 wherein the microtubule affecting agent is Taxotere. 21. The method of claim 18 wherein the proliferative disease is: prostate cancer, lung cancer, pancreatic cancer, colon cancer, or bladder carcinoma. 22. The method of claim 18 wherein the proliferative disease is prostate cancer. 23. The method of claim 18 wherein the proliferative disease is lung cancer. 24. The method of claim 18 wherein the proliferative disease is pancreatic cancer.

Details for Patent 6,333,333

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2017-12-22